BAY 80-6946 is a highly selective intravenous pI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models

Molecular Cancer Therapeutics

Volumn 12, Issue 11, 2013, Pages 2319-2330

  Liu, Ningshu ^a   Rowley, Bruce R ^a   Bull, Cathy O ^a   Schneider, Claudia ^a   Haegebarth, Andrea ^a   Schatz, Christoph A ^a   Fracasso, Paul R ^a   Wilkie, Dean P ^a   Hentemann, Martin ^a   Wilhelm, Scott M ^a   Scott, William J ^a   Mumberg, Dominik ^a   Ziegelbauer, Karl ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

9 (1 ANILINOETHYL) 7 METHYL 2 MORPHOLINOPYRIDO[1,2 A]PYRIMIDIN 4 ONE; ANTINEOPLASTIC AGENT; COPANLISIB; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FLUORODEOXYGLUCOSE F 18; LAPATINIB; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PICTILISIB; PROTEIN KINASE B; TRASTUZUMAB; UNCLASSIFIED DRUG; VINBLASTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG POTENCY; DRUG POTENTIATION; DRUG UPTAKE; HUMAN; HUMAN CELL; IC 50; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; NEOPLASM; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR CELL LINE; TUMOR REGRESSION; WILD TYPE; XENOGRAFT;

ADMINISTRATION, INTRAVENOUS; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; QUINAZOLINES; RATS; RATS, NUDE; RECEPTOR, ERBB-2; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84887453307     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296:1655-7.
2. Osaki M, Oshimura M, Ito H. PI3K-AKT pathway: its functions and alterations in human cancer. Apoptosis 2004;9:667-76.
3. Jimenez C, Hernandez C, Pimental B, Carrera AC. The p85 regulatory subunit controls sequential activation of phosphoinositide 3-kinase by Tyr kinases and Ras. J Biol Chem 2002;277:41556-62.
4. Wu H, Yan Y, Backer JM. Regulation of class IA PI3Ks. Biochem Soc Trans 2007;35:242-4.
5. Zhao L, Vogt PK. Class I PI3K in oncogenic cellular transformation. Oncogene 2008;27:5486-96.
6. Vogt PK, Hart JR, Gymnopoulos M, Jiang H, Kang S, Bader AG, et al. Phosphatidylinositol 3-kinase: the oncoprotein. Curr Top Microbiol Immunol 2010;347:79-104.
7. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
8. Ligresti G, Militello L, Steelman LS, Cavallaro A, Basile F, Nicoletti F, et al. PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Cell Cycle 2009;8:1352-8.
9. Georgescu MM. PTEN tumor suppressor network in PI3K-AKT pathway control. Genes Cancer 2010;1:1170-7.
10. Wee S, Wiederschain D, Maira SM, Loo A, Miller C, deBeaumont R, et al. PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci U S A 2008;105:13057-62.
11. Edgar KA, Wallin JJ, Berry M, Lee LB, Prior WW, Sampath D, et al. Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors. Cancer Res 2010;70:1164-72.
12. Dbouk HA, Backer JM. A beta version of life: p110b takes center stage.Oncotarget 2010;1:729-33.
13. Hsieh AC, Moasser MM. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 2007;97:453-7
14. Wong KK, Engelman JA, Cantley LC. Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev 2010;20:87-90
15. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6: 117-27.
16. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007;12:395-402.
17. Quentmeier H, Eberth S, Romani J, Zaborski M, Drexler HG. BCRABL1- independent PI3Kinase activation causing imatinib-resistance. J Hematol Oncol 2011;4:6.
18. Coffey JC, Wang JH, Smith MJ, Laing A, Bouchier-Hayes D, Cotter TG, et al. Phosphoinositide 3-kinase accelerates postoperative tumor growth by inhibiting apoptosis and enhancing resistance to chemotherapy- induced apoptosis. Novel role for an old enemy. J Biol Chem 2005;280:20968-77.
19. Kolasa IK, Rembiszewska A, Felisiak A, Ziolkowska-Seta I, Murawska M, Moes J, et al. PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients. Cancer Biol Ther 2009;8:21-6.
20. Gottschalk AR, Doan A, Nakamura JL, Stokoe D, Haas-Kogan DA. Inhibition of phosphatidylinositol-3-kinase causes increased sensitivity to radiation through a PKB-dependent mechanism. Int J Radiat Oncol Biol Phys 2005;63:1221-7.
21. Kim IA, Bae SS, Fernandes A, Wu J, Muschel RJ, McKenna WG, et al. Selective inhibition of Ras, phosphoinositide 3 kinase, and AKT isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer Res 2005;65:7902-10.
22. Markman B, Dienstmann R, Tabernero J. Targeting the PI3K/AKT/ mTOR pathway-beyond rapalogs. Oncotarget 2010;1:530-43.
23. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic- Huezo O, Serra V, et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011;19:58-71.
24. Jia S, Roberts TM, Zhao JJ. Should individual PI3 kinase isoforms be targeted in cancer? Curr Opin Cell Biol 2009;21:199-208.
25. Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, et al. Essential roles of PI (3)K-p110b in cell growth, metabolism, and tumorigenesis. Nature 2008;454:776-9.
26. Schneider C, Geenen E, Denner P, Prinz F, Mumberg D, Ziegelbauer K, et al. Molecular mechanisms by which BAY 80-6946 induces apoptosis in breast tumor cells as single agent or in combination [Abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, Florida. Philadelphia (PA): AACR; 2011. Abstract nr 3833.
27. Patnaik A, Appleman LJ, Mountz JM, Ramanathan RK, Beeram M, Tolcher AW, et al. A first-in-human phase I study of intravenous PI3K inhibitor BAY 80-6946 in patients with advanced solid tumors: results of dose-escalation phase. J ClinOncol 29:15s, 2011(suppl; abstract 3035).
28. Grana B, Burris HA, Rodon Ahnert J, Abdul Razak AR, De Jonge MJ, Eskens F, et al. Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: an update on safety and efficacy. J Clin Oncol 29:15s, 2011 (suppl; abstract 3043.28).
29. Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, et al. CAL-101, a p110d selective phosphatidylinositol- 3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011;117:591-4.
30. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008;7:1851-63.
31. O'Brien C, Wallin JJ, Sampath D, GuhaThakurta D, Savage H, Punnoose EA, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 30 kinase inhibitor GDC-0941 in breast cancer preclinical markers. Clin Cancer Res 2010;16:3670-83.
32. She QB, Chandarlapaty S, Ye Q, Lobo J, Haskell KM, Leander KR, et al. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS ONE 2008;3:e3065.
33. Raynaud FI, Eccles SA, Patel S, Alix S, Box G, Chuckowree I, et al. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther 2009;8:1725-38.
34. Tanaka H, Yoshida M, Tanimura H, Fujii T, Sakata K, Tachibana Y, et al. The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res 2011;17: 3272-81.
35. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, et al.MK-2206, an allostericAKT inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010;9:1956-67.
36. National Institutes of Health, US Department of Health and Human Services. ClinicalTrials.gov website. [Identifiers: NCT00962611, NCT01411410, NCT01392521; accessed 2011 Dec 15]. Available from: http://clinicaltrials.gov/ct2/home.